{"id":58846,"date":"2026-03-05T14:05:13","date_gmt":"2026-03-05T06:05:13","guid":{"rendered":"https:\/\/flcube.com\/?p=58846"},"modified":"2026-03-05T14:05:14","modified_gmt":"2026-03-05T06:05:14","slug":"eli-lillys-eloralintide-wins-cde-approval-for-phase-iii-trials-in-china-weekly-amylin-agonist-targets-weight-management-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58846","title":{"rendered":"Eli Lilly&#8217;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced that China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong> under the <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>Eloralintide<\/strong> to initiate <strong>three global pivotal Phase III clinical studies<\/strong> in China. The approval supports future registration for <strong>multiple indications, including weight management<\/strong>, marking a strategic expansion of Lilly&#8217;s metabolic portfolio into the world&#8217;s second\u2011largest pharmaceutical market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval for Phase III<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Eloralintide<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Three simultaneous global pivotal Phase III studies<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Multiple, including weight management<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>5\u202fMar\u202f2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Patient enrollment initiation; data to support future NDA submission<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Potent, selective, long\u2011acting <strong>Amylin Receptor Agonist (AMYR)<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Human amylin 1 receptor (AMY1R)<\/strong> with high affinity; selective over <strong>human calcitonin receptor (hCTR)<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Dual benefit of sustained weight loss with improved gastrointestinal tolerability through receptor selectivity, minimizing calcitonin\u2011related safety risks<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> <strong>Once\u2011weekly subcutaneous administration<\/strong> enabled by ~14\u2011day plasma half\u2011life<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Complements Lilly&#8217;s existing obesity portfolio (tirzepatide) with distinct amylin\u2011centric mechanism<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-strategy\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III (pivotal)<\/td><\/tr><tr><td><strong>Number of Studies<\/strong><\/td><td>3 concurrent global trials<\/td><\/tr><tr><td><strong>Geographic Inclusion<\/strong><\/td><td>China as part of global enrollment<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Weight reduction efficacy vs. placebo\/active comparator<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Glycemic control, cardiovascular markers, safety\/tolerability<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>China data to support simultaneous global registration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Obesity Market:<\/strong> With >50% of adults overweight\/obese and GLP\u20111 penetration still nascent, an amylin\u2011targeted therapy offers differentiation in a market projected to exceed <strong>$15\u202fbillion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Strategic Synergy:<\/strong> Eloralintide positions Lilly to capture patients seeking alternatives or adjuncts to incretin\u2011based therapies (GLP\u20111\/GIP)<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts estimate <strong>$2\u20134\u202fbillion peak annual sales<\/strong> globally if approved, with China contributing <strong>15\u201320%<\/strong> of volume given population scale<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Novo Nordisk&#8217;s amylin analog pramlintide requires multiple daily injections; Eloralintide&#8217;s weekly dosing provides clear convenience advantage<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Lilly plans to leverage existing biologics capacity in Suzhou, China to support regional supply chain efficiency<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for Eloralintide. Actual results may differ materially due to risks including trial enrollment delays, regulatory requirements, competitive dynamics, and manufacturing capabilities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced that China&#8217;s Center for Drug Evaluation (CDE) under&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58847,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,199,911,86],"class_list":["post-58846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that China&#039;s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly&#039;s metabolic portfolio into the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58846\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that China&#039;s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly&#039;s metabolic portfolio into the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58846\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T06:05:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T06:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market\",\"datePublished\":\"2026-03-05T06:05:13+00:00\",\"dateModified\":\"2026-03-05T06:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0503.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58846#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58846\",\"name\":\"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0503.webp\",\"datePublished\":\"2026-03-05T06:05:13+00:00\",\"dateModified\":\"2026-03-05T06:05:14+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced that China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly's metabolic portfolio into the world's second\u2011largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58846\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58846#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced that China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly's metabolic portfolio into the world's second\u2011largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58846","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market","og_description":"Eli Lilly and Company (NYSE: LLY) announced that China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly's metabolic portfolio into the world's second\u2011largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=58846","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T06:05:13+00:00","article_modified_time":"2026-03-05T06:05:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58846#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58846"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market","datePublished":"2026-03-05T06:05:13+00:00","dateModified":"2026-03-05T06:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58846"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58846#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","keywords":["Clinical trial approval \/ initiation","Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58846#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58846","url":"https:\/\/flcube.com\/?p=58846","name":"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58846#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58846#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","datePublished":"2026-03-05T06:05:13+00:00","dateModified":"2026-03-05T06:05:14+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced that China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has approved Eloralintide to initiate three global pivotal Phase III clinical studies in China. The approval supports future registration for multiple indications, including weight management, marking a strategic expansion of Lilly's metabolic portfolio into the world's second\u2011largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58846#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58846"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58846#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","width":1080,"height":608,"caption":"Eli Lilly's Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58846#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Eloralintide Wins CDE Approval for Phase III Trials in China \u2013 Weekly Amylin Agonist Targets Weight Management Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58846"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58846\/revisions"}],"predecessor-version":[{"id":58848,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58846\/revisions\/58848"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58847"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}